 | Patriot One Technologies Inc. - PAT.v aims to directly address the growing Active Threat phenomena which has become a significant force for shaping research in weapons detection. Portable devices and software solutions assist security personnel in the detection of concealed weapons. $ 1.94 Now $ 1.75 http://pennystockjournal.blogspot.ca/2017/10/patriot-one-technologies-inc-patv.html | Consolidating after financing. |
 | PyroGenesis Canada Inc. - PYR.v is a leader in the design, development, manufacture and commercialization of advanced plasma processes. $ .68 Now $ .63 http://pennystockjournal.blogspot.ca/2018/02/pyrogenesis-canada-inc-pyrv.html | Financing closed. |
 | Orca Gold Inc. - ORG.v is an exploration company focused in North and West Africa. Orca's flagship project is the Block 14 gold project, located in northern Sudan, near the border with Egypt. $ .53 Now $ .60 http://pennystockjournal.blogspot.ca/2018/02/orca-gold-inc-orgv.html | Red Back boys are drilling in Sudan. |
 | Pascal Biosciences Inc. - PAS.v is a biotechnology company focused on harnessing the body’s immune system to fight cancer. Last at $ .48 Now $ .56 http://pennystockjournal.blogspot.ca/2018/02/pascal-biosciences-inc-pasv.html | Juiced on big volume |
 | Canada Jetlines Ltd. - JET.v is set to become Canada’s first ultra-low fare airline. $ 1.13 Now $ .78 http://pennystockjournal.blogspot.ca/2018/03/canada-jetlines-ltd-jetv.html | Co's deal for leased aircaft fails, launch delayed. |
| Cornerstone Metals Inc. - CCC.v is advancing the flagship Carlin Vanadium Project. $ .41 Now $ .54 http://pennystockjournal.blogspot.ca/2018/03/cornerstone-metals-inc-cccv.html | Vanadium is hot. |
 | Antibe Therapeutics Inc. - ATE.v develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug is ATB-346. $ .48 Now $ .50 http://pennystockjournal.blogspot.ca/2018/03/antibe-therapeutics-inc-atev.html | Co's main drug passes trials. |
